T_Dia
02-16-2009, 04:50 PM
Arete Therapeutics, a biotechnology company, has initiated a Phase IIa clinical trial for AR9281, an orally-administered soluble epoxide hydrolase inhibitor being developed for the treatment of type 2 diabetes.
The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naive for type 2 diabetes medications.
The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.
Full Article (http://drugdiscovery.pharmaceutical-business-review.com/news/arete_therapeutics_initiates_phase_iia_diabetes_tr ial_160209).
The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naive for type 2 diabetes medications.
The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.
Full Article (http://drugdiscovery.pharmaceutical-business-review.com/news/arete_therapeutics_initiates_phase_iia_diabetes_tr ial_160209).